Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials

Dirk Arnold(Asklepios Klinik Altona), Fortunato Ciardiello(University of Campania "Luigi Vanvitelli")

Annals of Oncology

April 5, 2017

10.1093/annonc/mdx175

Cited by 829

Related Papers

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

|Annals of Oncology|2012|1.5k

Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2015|1.3k

Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2016|1.1k

Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial

|The Lancet Oncology|2015|723

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS

|Annals of Oncology|2017|591